phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"10.37489/2588-0527-2020-1-19-25phgenomics-183Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОГЕНЕТИКАCLINICAL PHARMACOGENETICSКлиническая фармакогенетика блокаторов рецепторов ангиотензина IIClinical pharmacogenetics of angiotensin II receptor blockershttps://orcid.org/0000-0002-9177-6642СиницинаИ. И.SinitsinaI. I.

Синицина Ирина Ивановна - д. м. н., доцент, профессор кафедры клинической фармакологии и терапии

Москва

Sinitsina Irina I. - Doctor of Medical Sciences, associate Professor, Professor of the Department of Clinical Pharmacology and Therapy

Moscow

sinitsina-irina@mail.ruhttps://orcid.org/0000-0002-9996-4621БояркоА. В.BoyarkoA. V.

Боярко Алексей Владимирович - врач

Москва

Boyarko Alexey V. - Doctor LLC LMS Clinic

Moscow

av.boyarko@mail.ruhttps://orcid.org/0000-0002-1242-0833ТемирбулатовИ. И.TemirbulatovI. I.

Темирбулатов Ильяс Ильдарович - ординатор кафедры клинической фармакологии и терапии

Москва

Moscow

temirbulatov.ilyas@gmail.comФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of RussiaRussian FederationООО «Клиника ЛМС»РоссияLLC LMS ClinicRussian Federation202008122020011925Copyright © Синицина И.И., Боярко А.В., Темирбулатов И.И., 20202020Синицина И.И., Боярко А.В., Темирбулатов И.И.Sinitsina I.I., Boyarko A.V., Temirbulatov I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/183

Представлен научный обзор актуальных данных о влиянии полиморфизма генов семейства цитохрома Р450 2C9 (CYP2C9), и генов, кодирующих компоненты ренин-ангиотензин-альдостероновой системы (РААС) на фармакокинетику и фармакодинамику блокаторов рецепторов ангиотензина II (БРА). Полиморфизм данных генов определяет вариабельность фармакологического ответа при применении препаратов этой группы. Рассмотрены вопросы влияния индивидуальных генетических факторов на эффективность антигипертензивной терапии, способствующих дифференцированному подходу в применении блокаторов рецепторов ангиотензина II (БРА).

This scientific review presents a current data on the effect of genetic polymorphism of CYP2C9 genes and genes encoding components of the renin-angiotensin-aldosterone system (RAAS) on the angiotensin II receptor blockers (ARBs) pharmacokinetics and pharmacodynamics. The data shows that genetic polymorphisms of these genes determine the large interindividual variability of the pharmacological response to ARBs. In this article, we carried out a comprehensive review of recent findings on interpatient variability in antihypertensive therapy response due to genetic factors and individualized treatment approach in ARBs therapy.

сартаныгенетический полиморфизмцитохром P450 2C9ренин–ангиотензин–альдостероновая система (РААС)sartansgenetic polymorphismcytochrome P450 2C9renin-angiotensin-aldosterone system (RAAS)ReferencesPonikowski P, Voors AA, Anker SD, et al 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016;37:2129-2200m. 10.1093/eurheartj/ehw128Ponikowski P, Voors AA, Anker SD, et al 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016;37:2129-2200m. 10.1093/eurheartj/ehw128Williams B, Mancia G, Spiering W, et al 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104. https://doi.org/10.1093/eurheartj/ehy339Williams B, Mancia G, Spiering W, et al 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104. https://doi.org/10.1093/eurheartj/ehy339Rodgers JE, Patterson JH (2001) Angiotensin II-receptor blockers: Clinical relevance and therapeutic role. Am. J. Heal. Pharm. 2001;58:671–683Rodgers JE, Patterson JH (2001) Angiotensin II-receptor blockers: Clinical relevance and therapeutic role. Am. J. Heal. Pharm. 2001;58:671–683Сычев Д.А., Раменская Г.В., Игнатьев И.В., Кукес В.Г. Клиническая фармакогенетика: Учебное пособие / Под ред. В.Г. Кукеса, Н.П. Бочкова.- М.:ГЭОТАР Медиа. 2007. [Sychev D.A., Ramenskaya G.V., Ignat'ev I.V., Kukes V.G. Klinicheskaya farmakogenetika: Uchebnoe posobie / Ed by V.G. Kukes, N.P. Bochkova.- M.:GEOTAR Media. 2007 (In Russ).]Сычев Д.А., Раменская Г.В., Игнатьев И.В., Кукес В.Г. Клиническая фармакогенетика: Учебное пособие / Под ред. В.Г. Кукеса, Н.П. Бочкова.- М.:ГЭОТАР Медиа. 2007. [Sychev D.A., Ramenskaya G.V., Ignat'ev I.V., Kukes V.G. Klinicheskaya farmakogenetika: Uchebnoe posobie / Ed by V.G. Kukes, N.P. Bochkova.- M.:GEOTAR Media. 2007 (In Russ).]Isvoran A, Louet M, Vladoiu DL, et al. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discov Today. 2017;22:366–376. https://doi.org/10.1016/j.drudis.2016.09.015Isvoran A, Louet M, Vladoiu DL, et al. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discov Today. 2017;22:366–376. https://doi.org/10.1016/j.drudis.2016.09.015Spiering W, Kroon AA, Fuss-Lejeune MJMJ, De Leeuw PW. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J Hypertens. 2005;23:753–758. https://doi.org/10.1097/01.hjh.0000163143.66965.06Spiering W, Kroon AA, Fuss-Lejeune MJMJ, De Leeuw PW. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J Hypertens. 2005;23:753–758. https://doi.org/10.1097/01.hjh.0000163143.66965.06Wang B, Wang J, Huang S-Q, et al. Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. Curr Drug Metab. 2009;10:781–834. https://doi.org/10.2174/138920009789895480Wang B, Wang J, Huang S-Q, et al. Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance. Curr Drug Metab. 2009;10:781–834. https://doi.org/10.2174/138920009789895480Zhou Y, Ingelman-Sundberg M, Lauschke VM (2017) Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clin Pharmacol Ther. 2017;102:688–700. https://doi.org/10.1002/cpt.690Zhou Y, Ingelman-Sundberg M, Lauschke VM (2017) Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clin Pharmacol Ther. 2017;102:688–700. https://doi.org/10.1002/cpt.690Мирзаев К.Б., Федоринов Д.С., Иващенко Д.В., Сычев Д.А. Мультиэтнический анализ кардиологических фармакогенетических маркеров генов цитохрома Р450 и мембранных транспортеров в российской популяции. Рациональная Фармакотерапия в Кардиологии 2019;15(3):393-406. [Mirzaev K.B., Fedorinov D.S., Ivashchenko D.V., Sychev D.A. Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome p450 and Membrane Transporters Genes in the Russian Population. Rational Pharmacotherapy in Cardiology 2019;15(3):393-406. (In Russ).] DOI:10.20996/1819-6446-2019-15-3-393-406Мирзаев К.Б., Федоринов Д.С., Иващенко Д.В., Сычев Д.А. Мультиэтнический анализ кардиологических фармакогене- тических маркеров генов цитохрома Р450 и мембранных транспортеров в российской популяции. Рациональная Фармакотерапия в Кардиологии 2019;15(3):393-406. [Mirzaev K.B., Fedorinov D.S., Ivashchenko D.V., Sychev D.A. Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome p450 and Membrane Transporters Genes in the Russian Population. Rational Pharmacotherapy in Cardiology 2019;15(3):393-406. (In Russ).] DOI:10.20996/1819-6446-2019-15-3-393-406Карева Е.Н. Эволюция сартанов или все ли сартаны одинаковы? Клин. фармакол. тер., 2016, 25 (3), 11-21. [Kareva E.N. Evolution of angiotensin receptor blockers. Clin. Pharmacol. Ther. 2016;25(3):11-21. (In Russ).]Карева Е.Н. Эволюция сартанов или все ли сартаны одинаковы? Клин. фармакол. тер., 2016, 25 (3), 11-21. [Kareva E.N. Evolution of angiotensin receptor blockers. Clin. Pharmacol. Ther. 2016;25(3):11-21. (In Russ).]Redon J, Fabia JM. Efficacy in angiotensin receptor blockade: A comparative review of data with olmesartan. JRAAS - J. Renin-Angiotensin-Aldosterone Syst. 2009;10:147–156Redon J, Fabia JM. Efficacy in angiotensin receptor blockade: A comparative review of data with olmesartan. JRAAS - J. Renin-Angiotensin-Aldosterone Syst. 2009;10:147–156Cabaleiro T, Román M, Ochoa D, et al. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos. 2013;41:224–229. https://doi.org/10.1124/dmd.112.046292Cabaleiro T, Román M, Ochoa D, et al. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos. 2013;41:224–229. https://doi.org/10.1124/dmd.112.046292Sica DA, Gehr TWB, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44:797–814. https://doi.org/10.2165/00003088-200544080-00003Sica DA, Gehr TWB, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44:797–814. https://doi.org/10.2165/00003088-200544080-00003Yasar U, Forslund-Bergengren C, Tybring G, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002;71:89–98. https://doi.org/10.1067/mcp.2002.121216Yasar U, Forslund-Bergengren C, Tybring G, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002;71:89–98. https://doi.org/10.1067/mcp.2002.121216Babaoglu MO, Yasar U, Sandberg M, et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol. 2004;60:337–342. https://doi.org/10.1007/s00228-004-0785-5Babaoglu MO, Yasar U, Sandberg M, et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol. 2004;60:337–342. https://doi.org/10.1007/s00228-004-0785-5Allabi AC, Gala JL, Horsmans Y, et al. Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans. Clin Pharmacol Ther. 2004;76:113–118. https://doi.org/10.1016/j.clpt.2004.04.001Allabi AC, Gala JL, Horsmans Y, et al. Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans. Clin Pharmacol Ther. 2004;76:113–118. https://doi.org/10.1016/j.clpt.2004.04.001Lee CR, Pieper JA, Hinderliter AL, et al. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy. 2003;23:720–725. https://doi.org/10.1592/phco.23.6.720.32187Lee CR, Pieper JA, Hinderliter AL, et al. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy. 2003;23:720–725. https://doi.org/10.1592/phco.23.6.720.32187Леонова М.В. Сартаны в лечении артериальной гипертонии: преимущества кандесартана. Consilium Medicum. 2019;21(1):25–30. [Leonova M.V. Sartany v lechenii arterial'noi gipertonii: preimushchestva kandesartana. Consilium Medicum. 2019;21(1):25–30. (in Russ.)] DOI:10.26442/20751753.2019.1.190280Леонова М.В. Сартаны в лечении артериальной гипертонии: преимущества кандесартана. Consilium Medicum. 2019;21(1):25–30. [Leonova M.V. Sartany v lechenii arterial'noi gipertonii: preimushchestva kandesartana. Consilium Medicum. 2019;21(1):25–30. (in Russ.)] DOI:10.26442/20751753.2019.1.190280Hallberg P, Karlsson J, Kurland L, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens. 2002;20:2089–2093. https://doi.org/10.1097/00004872-200210000-00030Hallberg P, Karlsson J, Kurland L, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens. 2002;20:2089–2093. https://doi.org/10.1097/00004872-200210000-00030Hong X, Zhang S, Mao G, et al. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol. 2005;61:627–634. https://doi.org/10.1007/s00228-005-0976-8Hong X, Zhang S, Mao G, et al. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol. 2005;61:627–634. https://doi.org/10.1007/s00228-005-0976-8Hanatani T. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics J. 2001;1:288–292. https://doi.org/10.1038/sj.tpj.6500063Hanatani T. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics J. 2001;1:288–292. https://doi.org/10.1038/sj.tpj.6500063Procopciuc L, Popescu T, Jebeleanu G, et al. Essential arterial hypertension and polymorphism of angiotensinogen M235T gene. J Cell Mol Med. 2002;6:245–250. https://doi.org/10.1111/j.1582-4934.2002.tb00191.xProcopciuc L, Popescu T, Jebeleanu G, et al. Essential arterial hypertension and polymorphism of angiotensinogen M235T gene. J Cell Mol Med. 2002;6:245–250. https://doi.org/10.1111/j.1582-4934.2002.tb00191.xZhou A, Carrell RW, Murphy MP, et al. A redox switch in angiotensinogen modulates angiotensin release. Nature. 2010;468:108–111. https://doi.org/10.1038/nature09505Zhou A, Carrell RW, Murphy MP, et al. A redox switch in angiotensinogen modulates angiotensin release. Nature. 2010;468:108–111. https://doi.org/10.1038/nature09505Муженя Д.В. Патофизиологическая роль и прогностическая значимость М235Т полиморфизма гена ангиотензиногена (AGТ) при болезнях сердечного континуума (БСК) // Вестн. Адыгейского гос. ун-та. Сер. 4: Естеств.-матем. и техн. науки. 2011. № 3. С. 69–81. [Pathophysiological role and the prognostic importance of the angiotensinogen (AGT) gene M235T polymorphism at illnesses of a heart continuum. Vestnik Adygeiskogo gosudarstvennogo universiteta, seriya «Estestvenno-matematicheskie i tekhnicheskie nauki 2011;(3):69–81. (in Russ.)]Муженя Д.В. Патофизиологическая роль и прогностическая значимость М235Т полиморфизма гена ангиотензиногена (AGТ) при болезнях сердечного континуума (БСК) // Вестн. Адыгейского гос. ун-та. Сер. 4: Естеств.-матем. и техн. науки. 2011. № 3. С. 69–81. [Pathophysiological role and the prognostic importance of the angiotensinogen (AGT) gene M235T polymorphism at illnesses of a heart continuum. Vestnik Adygeiskogo gosudarstvennogo universiteta, seriya «Estestvenno-matematicheskie i tekhnicheskie nauki 2011;(3):69–81. (in Russ.)]Страмбовская Н.Н. Прогностическая роль полиморфных вариантов генов-кандидатов у больны ишемическим инсультом в Забайкалье // Фундам. исследования. 2015. № 1. С. 140–144. [Strambovskaya N.N Рrognostic role genetic polymorphisms for ischemic stroke patients in transbaikal region. 2015;(1):140-144.(in Russ.)]Страмбовская Н.Н. Прогностическая роль полиморфных вариантов генов-кандидатов у больны ишемическим инсультом в Забайкалье // Фундам. исследования. 2015. № 1. С. 140–144. [Strambovskaya N.N Рrognostic role genetic polymorphisms for ischemic stroke patients in transbaikal region. 2015;(1):140-144.(in Russ.)]Watkins WS, Hunt SC, Williams GH, et al. Genotype-phenotype analysis of angiotensinogen polymorphisms and essential hypertension: The importance of haplotypes. J Hypertens. 2010;28:65–75. https://doi.org/10.1097/HJH.0b013e328332031aWatkins WS, Hunt SC, Williams GH, et al. Genotype-phenotype analysis of angiotensinogen polymorphisms and essential hypertension: The importance of haplotypes. J Hypertens. 2010;28:65–75. https://doi.org/10.1097/HJH.0b013e328332031aЗотова Т.Ю., Кубанова А.П., Азова М.М., Аит Аисса Амира. Особенности клинического течения артериальной гипертензии в зависимости от полиморфного варианта гена AGTR1. Клин. мед. 2017; 95(5):404-407. [Zotova T.Yu., Kubanova A.P., Azova M.M., Aut Aissa Amira Peculiarities of the clinical picture of arterial hypertension depending on polymorphic variant of AGTR1 gene. Klin. med. 2017;95(5):404-407. DOI http://dx.doi.org/10.18821/0023-2149-2017-95-5-404-407(in Russ.)]Зотова Т.Ю., Кубанова А.П., Азова М.М., Аит Аисса Амира. Особенности клинического течения артериальной гипертензии в зависимости от полиморфного варианта гена AGTR1. Клин. мед. 2017; 95(5):404-407. [Zotova T.Yu., Kubanova A.P., Azova M.M., Aut Aissa Amira Peculiarities of the clinical picture of arterial hypertension depending on polymorphic variant of AGTR1 gene. Klin. med. 2017;95(5):404-407. DOI http://dx.doi.org/10.18821/0023-2149-2017-95-5-404-407(in Russ.)]Redon J, Luque-Otero M, Martell N, et al. Renin-angiotensin system gene polymorphisms: Relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J. 2005;5:14–20. https://doi.org/10.1038/sj.tpj.6500280Redon J, Luque-Otero M, Martell N, et al. Renin-angiotensin system gene polymorphisms: Relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J. 2005;5:14–20. https://doi.org/10.1038/sj.tpj.6500280Van De Wal RMA, Van Veldhuisen DJ, Van Gilst WH, Voors AA. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: Controversial or common sense? Eur. Heart J. 2005;26:2361–2367Van De Wal RMA, Van Veldhuisen DJ, Van Gilst WH, Voors AA. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: Controversial or common sense? Eur. Heart J. 2005;26:2361–2367Zhang H, Sun M, Sun T, et al. Association between angiotensin II type 1 receptor gene polymorphisms and ischemic stroke: A meta-analysis. Cerebrovasc Dis. 2011;32:431–438. https://doi.org/10.1159/000330655Zhang H, Sun M, Sun T, et al. Association between angiotensin II type 1 receptor gene polymorphisms and ischemic stroke: A meta-analysis. Cerebrovasc Dis. 2011;32:431–438. https://doi.org/10.1159/000330655Szolnoki Z, Havasi V, Talián G, et al. Angiotensin II type-1 receptor A1166C polymorphism is associated with increased risk of ischemic stroke in hypertensive smokers. J Mol Neurosci. 2006;28:285–290. https://doi.org/10.1385/JMN:28:3:285Szolnoki Z, Havasi V, Talián G, et al. Angiotensin II type-1 receptor A1166C polymorphism is associated with increased risk of ischemic stroke in hypertensive smokers. J Mol Neurosci. 2006;28:285–290. https://doi.org/10.1385/JMN:28:3:285Rubattu S, Di Angelantonio E, Stanzione R, et al. Gene polymorphisms of the renin-angiotensin-aldosterone system and the risk of ischemic stroke: A role of the A1166C/AT1 gene variant. J Hypertens. 2004;22:2129–2134. https://doi.org/10.1097/00004872-200411000-00015Rubattu S, Di Angelantonio E, Stanzione R, et al. Gene polymorphisms of the renin-angiotensin-aldosterone system and the risk of ischemic stroke: A role of the A1166C/AT1 gene variant. J Hypertens. 2004;22:2129–2134. https://doi.org/10.1097/00004872-200411000-00015Weekers L, Bonhanick B, Hadjadj S, et al. Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients. Diabetes. 2005;54:2961–2967. https://doi.org/10.2337/diabetes.54.10.2961Weekers L, Bonhanick B, Hadjadj S, et al. Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients. Diabetes. 2005;54:2961–2967. https://doi.org/10.2337/diabetes.54.10.2961Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005;111:3374–3383. https://doi.org/10.1161/CIRCULATIONAHA.104.504639Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005;111:3374–3383. https://doi.org/10.1161/CIRCULATIONAHA.104.504639Kurland L, Melhus H, Karlsson J, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens. 2002;20:657–663. https://doi.org/10.1097/00004872-200204000-00023Kurland L, Melhus H, Karlsson J, et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens. 2002;20:657–663. https://doi.org/10.1097/00004872-200204000-00023Conrady AO, Kiselev IO, Usachev NI, et al. (2005) Effect of 24-week treatment with telmisartan on myocardial structure and function: Relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene. J Int Med Res. 2005;33 Suppl 1:30A-38A. https://doi.org/10.1177/14732300050330s105Conrady AO, Kiselev IO, Usachev NI, et al. (2005) Effect of 24-week treatment with telmisartan on myocardial structure and function: Relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene. J Int Med Res. 2005;33 Suppl 1:30A-38A.Jia M, Yang B, Li Z, et al. Computational analysis of functional single nucleotide polymorphisms associated with the CYP11B2 gene. PLoS One. 2014; 7;9(8):e104311. https://doi.org/10.1371/journal.pone.0104311https://doi.org/10.1177/14732300050330s105Heller S, Linhart A, Jindra A, et al. Association of -344/T/C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men. Blood Press. 2004;13:158–163. https://doi.org/10.1080/08037050410035554Jia M, Yang B, Li Z, et al. Computational analysis of functional single nucleotide polymorphisms associated with the CYP11B2 gene. PLoS One. 2014; 7;9(8):e104311Ortlepp JR, Hanrath P, Mevissen V, et al. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol. 2002;445:151–152. https://doi.org/10.1016/S0014-2999(02)01766-1https://doi.org/10.1371/journal.pone.0104311Wang L, Zhang Z, Liu D, et al (2020) Association of −344C/T polymorphism in the aldosterone synthase (CYP11B2) gene with cardiac and cerebrovascular events in Chinese patients with hypertension. J Int Med Res. 2020;48(9):300060520949409. https://doi.org/10.1177/0300060520949409Heller S, Linhart A, Jindra A, et al. Association of -344/T/C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men. Blood Press. 2004;13:158–163. https://doi.org/10.1080/08037050410035554Pi Y, Zhang L li, Chang K, et al. Lack of an Association between CYP11B2 C-344T Gene Polymorphism and Ischemic Stroke: A Meta-Analysis of 7,710 Subjects. PLoS One. 2013;8(8):e68842. https://doi.org/10.1371/journal.pone.0068842Ortlepp JR, Hanrath P, Mevissen V, et al. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol. 2002;445:151–152. https://doi.org/10.1016/S0014-2999(02)01766-1Androulakis E, Tousoulis D, Miliou A, et al. The impact of an aldosterone synthase (CYP11B2) polymorphism on vascular function and inflammatory biomarkers in essential hypertension. J Am Coll Cardiol. 2012;59:E1634. https://doi.org/10.1016/s0735-1097(12)61635-0Wang L, Zhang Z, Liu D, et al (2020) Association of −344C/T polymorphism in the aldosterone synthase (CYP11B2) gene with cardiac and cerebrovascular events in Chinese patients with hypertension. J Int Med Res. 2020;48(9):300060520949409. https://doi.org/10.1177/0300060520949409Chandra S, Saluja D, Narang R, et al. Atrial natriuretic peptide and aldosterone synthase gene in essential hypertension: A case-control study. Gene. 2015;567:92–97. https://doi.org/10.1016/j.gene.2015.04.062Pi Y, Zhang L li, Chang K, et al. Lack of an Association between CYP11B2 C-344T Gene Polymorphism and Ischemic Stroke: A Meta-Analysis of 7,710 Subjects. PLoS One. 2013;8(8):e68842.Byrd JB, Auchus RJ, White PC (2015) Aldosterone Synthase Promoter Polymorphism and Cardiovascular Phenotypes in a Large, Multiethnic Population-Based Study. J Investig Med. 2015;63:862–866. https://doi.org/10.1097/JIM.0000000000000220https://doi.org/10.1371/journal.pone.0068842Androulakis E, Tousoulis D, Miliou A, et al. THE IMPACT OF AN ALDOSTERONE SYNTHASE (CYP11B2) POLYMORPHISM ON VASCULAR FUNCTION AND INFLAMMATORY BIOMARKERS IN ESSENTIAL HYPERTENSION. J Am Coll Cardiol. 2012;59:E1634. https://doi.org/10.1016/s0735-1097(12)61635-0Androulakis E, Tousoulis D, Miliou A, et al. THE IMPACT OF AN ALDOSTERONE SYNTHASE (CYP11B2) POLYMORPHISM ON VASCULAR FUNCTION AND INFLAMMATORY BIOMARKERS IN ESSENTIAL HYPERTENSION. J Am Coll Cardiol. 2012;59:E1634. https://doi.org/10.1016/s0735-1097(12)61635-0Chandra S, Saluja D, Narang R, et al. Atrial natriuretic peptide and aldosterone synthase gene in essential hypertension: A case-control study. Gene. 2015;567:92–97. https://doi.org/10.1016/j.gene.2015.04.062Chandra S, Saluja D, Narang R, et al. Atrial natriuretic peptide and aldosterone synthase gene in essential hypertension: A case-control study. Gene. 2015;567:92–97. https://doi.org/10.1016/j.gene.2015.04.062Byrd JB, Auchus RJ, White PC (2015) Aldosterone Synthase Promoter Polymorphism and Cardiovascular Phenotypes in a Large, Multiethnic Population-Based Study. J Investig Med. 2015;63:862–866. https://doi.org/10.1097/JIM.0000000000000220Byrd JB, Auchus RJ, White PC (2015) Aldosterone Synthase Promoter Polymorphism and Cardiovascular Phenotypes in a Large, Multiethnic Population-Based Study. J Investig Med. 2015;63:862–866. https://doi.org/10.1097/JIM.0000000000000220

The authors declare that there are no conflicts of interest present.